Clinical Trial Update: Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating patient retention of fingolimod compared with currently approved disease-modifying therapies in relapsing-remitting multiple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Fingolimod (fingolimod)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 4 | Status: COMPLETED | Results posted: 2018-01-12